Slide 1

Previous Page

Next Page

Page Background

Maintenance therapy in DLBCL

Crump et al. JCO 2016

Enzastaurin

Everolimus

Rituximab

DFS 0.92 (0.69–1.22)

OS 0.75 (0.51–1.10)

Witzig et al. ASCO 2016

Jaeger et al. Haematologica 2015